The M&A Hunter (@maandhunter): "Context Therapeutics LLC CNTX $2.93 $0.28 (10.56%) today Context Therapeutics LLC is UpToday at 9:13 AM Context Therapeutics receives Fast Track Designation for CTIM-76. This drug targets platinum-resistant ovarian cancer and is currently in Phase 1 trials."

The app for independent voices

The M&A Hunter

6d

@maandhunter

Context Therapeutics LLC CNTX

$2.93

$0.28 (10.56%) today

Context Therapeutics LLC is UpToday at 9:13 AM

Context Therapeutics receives Fast Track Designation for CTIM-76. This drug targets platinum-resistant ovarian cancer and is currently in Phase 1 trials.

Apr 2

at

2:48 PM

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

The app for independent voices

Log in or sign up